What is Onc.AI?
Onc.AI is at the forefront of precision oncology, leveraging a rapidly expanding real-world dataset to power multimodal AI predictions. The company is dedicated to developing a pipeline of physician-centered products designed to unlock the full potential of personalized cancer treatment. Comprised of entrepreneurs, operators, and scientists with deep expertise spanning oncology, predictive analytics, computer vision, medical imaging, enterprise software, and AI/ML, Onc.AI is uniquely positioned to address complex challenges in cancer care.
How much funding has Onc.AI raised?
Onc.AI has raised a total of $31M across 2 funding rounds:
Unspecified
$6M
Series A
$25M
Unspecified (2020): $6M with participation from Accomplice, The Blue Venture Fund, KdT Ventures, and Digitalis Ventures
Series A (2023): $25M led by Digitalis Ventures, MassMutual, The Blue Venture Fund, Action Potential Venture Capital, and Accomplice
Key Investors in Onc.AI
Digitalis Ventures
Digitalis Ventures engineers solutions to unmet needs in health by leveraging deep technical, financial, and domain expertise. The company invests in biotechnology and technology-enabled solutions aimed at improving human and animal health while reducing costs. Their multidisciplinary team focuses on creatively financing, building, and scaling enduring enterprises.
MassMutual
MassMutual, formally known as Massachusetts Mutual Life Insurance Company, is a mutual life insurance company headquartered in Springfield, Massachusetts, that specializes in providing life insurance, retirement planning, and financial services to individuals, families, and businesses.
The Blue Venture Fund
The Blue Venture Fund is a unique partnership among Blue Cross Blue Shield companies aimed at advancing the healthcare industry through investments in technology, services, and clinical sciences. The fund focuses on improving health outcomes and delivering superior value to patients by connecting portfolio companies with Blue Plans and their members.
What's next for Onc.AI?
The recent major strategic investment signals a new phase of accelerated development and market penetration for Onc.AI. This capital infusion is expected to fuel the expansion of its AI-driven product pipeline and enhance its real-world dataset capabilities. With a clear focus on physician-centered solutions, Onc.AI is poised to further solidify its position as a leader in precision oncology, driving innovation and improving patient outcomes through advanced predictive analytics and AI.
See full Onc.AI company page
